Actavis plc’s acquisition of Forest Laboratories, Inc. shouldn’t result in decreased competition in the market for four generic drugs as a result of a settlement approved by the FTC.
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch